This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Anemia due to glucose-6-phosphate dehydrogenase deficiency(G6PD deficiency anemia)(Anaemia due to glucose-6-phosphate dehydrogenase (G6PD) deficiency)

Classification codes: ICD-10 D55.0 / V163  |  Synonyms: G6PD deficiency anemia, G6PD deficiency, favism, Glucose-6-phosphate dehydrogenase deficiency  |  Adult onset: not low (mild G6PD deficiency is asymptomatic until exposure to triggering drugs/foods, so it may first be discovered in adulthood through hemolysis after drug administration)

Contents


1. History

Antimalarials and the discovery of drug-induced hemolysis

The history of G6PD deficiency begins with antimalarial drug research during World War II. In the early 1950s, during clinical trials of primaquine at the US Army medical research laboratory, severe hemolytic anemia was observed in some African American soldiers. Because this phenomenon appeared only in certain races and individuals, it suggested that the cause was patient-specific susceptibility rather than the toxicity of the drug itself. In 1956, Paul E. Carson and colleagues discovered that the cause of this susceptibility was deficiency of glucose-6-phosphate dehydrogenase (G6PD) activity in red blood cells, which was one of the first cases explaining drug susceptibility at the genetic level.

Fava beans and Pythagoras: an ancient clue

The relationship between G6PD deficiency and fava beans (broad bean, Vicia faba) dates back to antiquity. Pythagoras (c. 570–495 BC) is known to have forbidden eating fava beans, and as a medical background to this taboo, some scholars suggest that he may have empirically recognized fava bean-induced hemolysis due to G6PD deficiency. Around the Mediterranean, the phenomenon of jaundice and anemia appearing in certain people after eating fava beans had been known for thousands of years.

Malaria resistance and evolutionary selective pressure

In the 1960s, research by Ernest Beutler and others confirmed that G6PD deficiency provides partial resistance to the malaria parasite (Plasmodium falciparum). This explains in evolutionary terms why G6PD deficiency is maintained at high frequency in malaria-endemic regions. Proliferation of malaria parasites is suppressed in G6PD-deficient red blood cells, and the possibility has also been raised that deficient red blood cells are selectively removed in the spleen.


2. Causes

Role of the G6PD enzyme

Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme of the pentose phosphate pathway (hexose monophosphate shunt, HMP shunt). This enzyme oxidizes glucose-6-phosphate to 6-phosphogluconolactone while reducing NADP⁺ to NADPH. The NADPH produced is used by glutathione reductase to reduce oxidized glutathione (GSSG) to reduced glutathione (GSH). GSH is the key antioxidant that protects red blood cells from oxidative damage. Because red blood cells have no mitochondria, the HMP shunt is the only pathway that produces NADPH, so G6PD is an enzyme essential for red blood cell survival.

Triggering factors

G6PD deficiency itself is often asymptomatic, and acute hemolysis occurs on exposure to triggering factors that cause external oxidative stress. The main triggering factors are: fava beans (Vicia faba, favism), antimalarials (primaquine, chloroquine, quinine, etc.), sulfonamides (sulfamethoxazole, etc.), nitrofurantoin, dapsone, naphthalene (mothballs), certain chemicals (phenylhydrazine), infections (increased oxidative stress during viral and bacterial infections), and neonatal jaundice (the neonatal period, vulnerable to oxidative stress). Among these, fava beans cause strong oxidative stress through their vicine and convicine components.


3. Genetics

The G6PD gene and X-linked inheritance

The G6PD gene is located on the long arm of the X chromosome (Xq28) and encodes a 515-amino-acid protein from 13 exons. The mode of inheritance is X-linked recessive. Therefore, males (XY) are hemizygous, and G6PD deficiency is expressed even if they carry only one variant allele. In heterozygous females (XX), one of the two X chromosomes is randomly inactivated (X-inactivation, lyonization), so G6PD activity varies among individuals, and some develop symptoms.

Types of variants and WHO classification

More than 200 variants of the G6PD gene have been reported worldwide. The World Health Organization (WHO) classifies G6PD deficiency by enzyme activity and clinical symptoms as follows: Class I (severe deficiency, <10% activity, chronic nonspherocytic hemolytic anemia), Class II (moderate to severe, <10% activity, acute hemolysis triggered by precipitating factors), Class III (mild, 10–60% activity, intermittent hemolysis triggered by precipitating factors), and Class IV (normal, activity >60%). The African type G6PD A- (Class III) and the Mediterranean type G6PD Med (Class II) are most often mentioned.

Major variants by region

G6PD A- (African type) carries the double variant V68M (or G202A) and A376G, occurs frequently mainly in sub-Saharan Africa and populations of African descent, and because the deficiency is relatively mild, drug-induced hemolysis rather than reaction to fava beans is the main clinical problem. G6PD Med (Mediterranean type) carries the C563T (Ser188Phe) variant, is common in Mediterranean, Middle Eastern, and South Asian populations, and shows more severe deficiency. Asian types include many variants such as G6PD Canton (R459L) and G6PD Mahidol.


4. General epidemiology

Worldwide prevalence

G6PD deficiency is the most common enzyme deficiency disorder in the world, with an estimated 400–500 million people affected worldwide. Prevalence varies greatly by region and is reported at various frequencies in Africa (5–25%), the Mediterranean (1–8%), the Middle East (5–10%), Southeast Asia (2–10%), and Korea (0.1–0.3% in males).

Regional distribution and association with malaria

Regions with a high frequency of G6PD deficiency almost coincide with past or present malaria-endemic regions. This is strong epidemiological evidence suggesting that G6PD deficiency confers a natural selective advantage against malaria. In particular, studies have reported lower malaria mortality in women heterozygous for G6PD deficiency.

Status in Korea

In Korea, the prevalence of G6PD deficiency is reported at about 0.1–0.3% in males, which is low compared with Western countries and Southeast Asia. Hemolytic episodes related to G6PD deficiency in Korea are rare, but they are reported intermittently in travelers taking antimalarial prophylaxis and in patients given certain drugs (sulfonamides, nitrofurantoin, etc.). Because G6PD deficiency is not included in newborn screening for inborn errors of metabolism in Korea, many cases are first diagnosed in adulthood through a drug reaction.


5. Pathophysiology

Oxidative stress and red blood cell vulnerability

In G6PD-deficient red blood cells, NADPH production is reduced because of impaired HMP shunt function, and accordingly GSH (reduced glutathione) levels cannot be maintained. On exposure to oxidative stressors, oxidative reactions within red blood cells accelerate, causing oxidative denaturation of hemoglobin (methemoglobin formation, hemoglobin precipitation), and aggregates of denatured hemoglobin attach to the red cell membrane to form Heinz bodies. Red blood cells containing Heinz bodies are selectively destroyed in the spleen (extravascular hemolysis) or rupture directly within blood vessels (intravascular hemolysis).

Acute hemolytic episodes

Acute hemolysis occurs within hours to days after exposure to a triggering factor. Hemolysis is often relatively self-limited, because in the G6PD A- type, young red blood cells such as reticulocytes have relatively higher G6PD activity than older red blood cells and are less vulnerable to oxidative stress. In contrast, in G6PD Med (Mediterranean type), enzyme activity is severely reduced in red blood cells of all ages, resulting in more extensive and persistent hemolysis.

Neonatal jaundice and chronic hemolysis

In neonatal G6PD deficiency, severe neonatal jaundice can occur after birth even in the absence of oxidative stress. Jaundice tends to worsen when, in addition to hemolysis, polymorphisms in genes related to bilirubin binding, conjugation, and excretion (especially UGT1A1) coexist. In Class I G6PD variants, persistent chronic nonspherocytic hemolytic anemia (CNSHA) occurs regardless of triggering factors.


6. Symptoms

Symptoms of acute hemolytic episodes

Symptoms of an acute G6PD hemolytic episode appear within hours to days after exposure to a triggering factor. Initially, fatigue, weakness, pallor, and jaundice (including scleral icterus) appear. When hemolysis is severe, dark brown or blackish-brown urine (hemoglobinuria) occurs, which is direct evidence of intravascular hemolysis. Abdominal pain, back pain, headache, and fever may also be present.

Complications of severe hemolysis

In severe hemolytic episodes, acute renal failure may occur due to renal tubular toxicity from hemoglobinuria, which is a life-threatening complication. Severe anemia (hemoglobin <7 g/dL) may lead to heart failure, shock, and tissue hypoxia. In neonates, there is a risk of neurological sequelae due to kernicterus.

Chronic nonspherocytic hemolytic anemia (Class I)

In extremely rare Class I G6PD variants, chronic hemolytic anemia persists even without triggering factors. Patients experience persistent jaundice, splenomegaly, and cholelithiasis (hemolytic gallstones) and are highly transfusion-dependent. Episodes of paroxysmal hemolysis (aplastic/hemolytic crisis), in which anemia worsens rapidly during infection or stress, may also occur.


7. Signs

Hematologic findings

In acute hemolytic episodes, the peripheral blood smear provides important diagnostic clues. Heinz bodies are identified as blue-violet deposits within red blood cells on crystal violet staining. Schistocytes, spherocytes, and ghost cells are observed, and the reticulocyte count increases. Hemoglobin decreases, total bilirubin (especially indirect bilirubin) and LDH increase, and haptoglobin decreases or falls to undetectable levels.

Urine findings

When intravascular hemolysis is severe, urine turns dark brown to reddish-brown due to hemoglobinuria. The urine occult blood reaction is positive, and urine hemoglobin can be detected directly. With severe renal tubular injury, serum creatinine and blood urea nitrogen (BUN) rise.

Physical examination findings

In acute episodes, conjunctival jaundice, pallor, and tachycardia appear. Splenomegaly may be observed in patients with Class I chronic hemolytic anemia. In neonatal G6PD deficiency, yellow discoloration of the sclera and skin and lethargy due to severe jaundice appear, and with progression to kernicterus, neurological signs (abnormal muscle tone, opisthotonus, eye abnormalities) are observed.


8. Screening

Fluorescent spot test and colorimetric assay

The fluorescent spot test is used as the standard screening test for G6PD deficiency. The principle is that when G6PD activity is present, the blood spot fluoresces under ultraviolet light, but in G6PD deficiency, no fluorescence appears. This test has high sensitivity and specificity and low cost and is also used as a point-of-care test. The colorimetric assay is a quantitative method that directly measures the rate of NADPH production using a spectrophotometer.

WHO-recommended screening strategy

The WHO recommends newborn screening in regions with a high prevalence of G6PD deficiency and recommends G6PD testing before prescribing hemolysis-inducing drugs such as primaquine. In particular, G6PD testing must be performed before using primaquine or tafenoquine for malaria treatment and prevention.

Newborn screening

Many countries include G6PD deficiency in newborn screening, but Korea currently does not. In regions with high G6PD prevalence, newborn G6PD testing is important for preventing kernicterus, and early testing is performed when suspected, particularly in newborns of Asian, African, or Mediterranean origin.


9. Diagnosis

Measurement of G6PD enzyme activity

G6PD deficiency is confirmed by measurement of G6PD enzyme activity. G6PD activity relative to red blood cell hemoglobin concentration (U/g Hb) is measured by spectrophotometric assay. The normal value in adults is about 8–18 U/g Hb; Class I is <1 U/g Hb, and Class II/III are at levels of 1–9 U/g Hb. Note that immediately after an acute hemolytic episode, G6PD activity may be temporarily elevated because of increased reticulocytes, so repeating the test after recovery from hemolysis (about 4–8 weeks later) helps obtain accurate results.

Genetic testing

G6PD genetic testing is used for confirmation and classification of variant type, identification of heterozygous females, and genetic counseling. Variants are identified by PCR-RFLP, direct sequencing, NGS panel testing, and other methods. In particular, heterozygous females may carry a G6PD deficiency allele even when their G6PD enzyme activity is within the normal range, so genetic testing is decisive for diagnosis when there is a family history.

Differential diagnosis of anemia

Hemolytic anemia due to G6PD deficiency must be differentiated from other hereditary or acquired hemolytic anemias. The main differential diagnoses include hereditary spherocytosis, pyruvate kinase deficiency, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura (TTP), and hemolytic uremic syndrome (HUS).


10. Treatment

Removal of triggering factors

The most important treatment of an acute G6PD hemolytic episode is immediate discontinuation of the triggering factor. When the causative drug, such as primaquine, sulfonamides, or nitrofurantoin, is stopped, hemolysis resolves spontaneously in most cases. In the G6PD A- type, hemolysis recovers in a self-limited manner as young red blood cells with higher enzyme activity are replenished.

Transfusion and supportive care

In severe anemia (hemoglobin <7 g/dL or severe symptoms), red blood cell transfusion is required. To prevent acute renal failure due to hemoglobinuria, urine output is maintained with adequate fluid administration, and renal replacement therapy (dialysis) is considered if severe renal failure develops. In neonatal G6PD jaundice, phototherapy is performed, and exchange transfusion is performed when bilirubin reaches a dangerous level.

Management of Class I chronic hemolytic anemia

Patients with chronic nonspherocytic hemolytic anemia due to Class I G6PD deficiency may need regular transfusions, and chelation therapy is considered to prevent iron overload due to persistent hemolysis. Folic acid supplementation is given as an adjunct, and splenectomy is sometimes considered for severe splenomegaly.


11. Prognosis

Good prognosis in most cases

Most patients with G6PD deficiency, especially those with Class II/III, can live a near-normal life if they avoid triggering factors. Acute hemolytic episodes are mostly self-limited, and hemoglobin recovers within days to weeks once the triggering factor is removed. Prognosis depends on the severity of G6PD deficiency and the strength of the triggering factor.

Severe episodes and risk of complications

When complications such as acute renal failure, heart failure, and shock occur in severe hemolytic episodes, the prognosis may become poor. However, most patients recover with appropriate treatment. If neonatal G6PD jaundice is not treated appropriately and kernicterus develops, permanent neurological damage may remain.

Interaction with malaria

In malaria-endemic regions, patients with G6PD deficiency face restrictions on the use of drugs with hemolytic risk, such as primaquine, when treating malaria, so treatment options may be limited. In addition, because infection itself can worsen acute hemolysis in patients with G6PD deficiency, infection management is also important.


12. Prevention

Education on and avoidance of triggering factors

The most important preventive measure after a diagnosis of G6PD deficiency is clearly educating patients and families about triggering factors. Main items to avoid: fava beans (Vicia faba) and related foods, antimalarials such as primaquine and chloroquine, sulfonamides, nitrofurantoin, dapsone, naphthalene mothballs, high-dose ascorbic acid, etc. Because some drugs available without a prescription can also cause hemolysis in G6PD deficiency, it is recommended to inform all clinicians of one's G6PD deficiency status.

Genetic counseling

Because it is an X-linked recessive genetic disease, identification of carriers (heterozygous females) and genetic counseling for family members are important for prevention. In particular, in pregnant women from regions with high prevalence, it is necessary to determine in advance the possibility of G6PD deficiency in the fetus and to prepare for the management of neonatal jaundice after birth.

Newborn screening and notification of medical institutions

In regions with a high prevalence of G6PD deficiency, newborn screening is effective in preventing kernicterus. Diagnosed patients should wear a medical alert bracelet (MedicAlert bracelet) or have their condition clearly noted in their medical records so that it can be communicated immediately to clinicians in emergencies.


13. References

  1. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124(3220):484-485.
  2. Beutler E. G6PD deficiency. Blood. 1994;84(11):3613-3636.
  3. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67(6):601-611.
  4. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74.
  5. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136(11):1225-1240.
  6. Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-278.
  7. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277-1282.
  8. Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood. 2020;136(11):1274-1283.
  9. Bancone G, Chu CS. G6PD variants and haemolytic sensitivity to primaquine and other drugs. Front Pharmacol. 2021;12:638885.
  10. Kim J, Kim JE, et al. Clinical features of glucose-6-phosphate dehydrogenase deficiency in Korean patients. Korean J Hematol. 2010;45(3):196-199.
  11. Cunningham AD, Hwang S, Bhatt DL. Glucose-6-phosphate dehydrogenase (G6PD) deficiency and red blood cell hemolysis. Curr Opin Hematol. 2021;28(3):213-220.
  12. Minucci A, Moradkhani K, Hwang MJ, et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the "old" and update of the new mutations. Blood Cells Mol Dis. 2012;48(3):154-165.